In summary, our preclinical data support the initiation of clinical studies evaluating enzalutamide for treatment of AR + tumors regardless of ER status, since enzalutamide uniquely blocks both androgen-mediated and estrogen-mediated tumor growth. Here, ESR1 is linked to neoplasm.